Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression

Experimental Hematology

Volumn 37, Issue 6, 2009, Pages 659-672

  Doubek, Michael ^a   Palasek, Ivo ^a   Pospisil, Zdenek ^b   Borsky, Marek ^a   Klabusay, Martin ^a   Brychtova, Yvona ^a   Jurcek, Tomas ^a   Jeziskova, Ivana ^a   Krejci, Marta ^a   Dvorakova, Dana ^a   Mayer, Jiri ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; INTERLEUKIN 2; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; MOLECULAR MARKER; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; BLOOD; BONE MARROW CELL; CBFB; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GENE; GENE EXPRESSION; GENE FUSION; GENE TRANSLOCATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; CASE-CONTROL STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; RECURRENCE; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 65649144793     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.03.004     Document Type: Article

References (29)

1. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
2. Tobal K., Newton J., Macheta M., et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95 (2000) 815-819
3. Scholl C., Schlenk R.F., Eiwen K., et al. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90 (2005) 1626-1634
4. Perea G., Lasa A., Aventín A., et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 20 (2006) 87-94
5. Doubek M., Brychtova Y., Berkovcova J., et al. Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy. Leukemia 19 (2005) 885-888
6. Trka J., Kalinova M., Hrusak O., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16 (2002) 1381-1389
7. Østergaard M., Olesen L.H., Hasle H., et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 125 (2004) 590-600
8. Weisser M., Kern W., Rauhut S., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19 (2005) 1416-1423
9. Kim H.R., Shin J.H., Lee J.N., and Lee E.Y. Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia. Korean J Lab Med 27 (2007) 305-312
10. Gabert J., Beillard E., van der Velden V.H.J., et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer Program. Leukemia 17 (2003) 2318-2357
11. Beillard E., Pallisgaard N., van der Velden V.H.J., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using real-time quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe Against Cancer Program. Leukemia 17 (2003) 2474-2486
12. Andersson A., Höglund M., Johansson B., et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia 15 (2001) 1293-1300
13. Kreuzer K.-A., Saborowski A., Lupberger J., et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 114 (2001) 313-318
14. Boublikova L., Kalinova M., Ryan J., et al. Wilmśtumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20 (2006) 254-263
15. Mehta J., Powles R., Singhal S., et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 16 (1995) 133-137
16. Raff T., Gökbuget N., Lüschen S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109 (2007) 910-915
17. Wassmann B., Pfeifer H., Stadler M., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 106 (2005) 458-463
18. Lo-Coco F., Cimino G., Breccia M., et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104 (2004) 1995-1999
19. Schwarz J., Marková J., Peková S., et al. A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia. Hematol J 5 (2004) 279-280
20. Grimwade D.J., Jovanovic J., Hills R., et al. Evaluation of prospective detection of PML-RARA and RARA-PML fusion transcripts by real-time quantitative PCR (RQ-PCR) to direct pre-emptive therapy with arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) patients treated in the UK MRC AML15 Trial. Blood 110 Suppl 1 (2007) Abstract 541
21. Schnittger S., Weisser M., Schoch C., et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102 (2003) 2746-2755
22. Viehmann S., Teigler-Schlegel A., Bruch J., et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 17 (2003) 1130-1136
23. Guerrasio A., Pilatrino C., De Micheli D., et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16 (2002) 1176-1181
24. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25 (2007) 4938-4945
25. Büchner T., Hiddemann W., Berdel W.E., et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21 (2003) 4496-4504
26. Yang L., Han Y., Saurez Saiz F., and Minden M.D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21 (2007) 868-876
27. Maurillo L., Buccisano F., Spagnoli A., et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 92 (2007) 605-611
28. Bonnet D. Normal and leukaemic stem cells. Br J Haematol 130 (2005) 469-479
29. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from primitive hematopoietic cells. Nat Med 3 (1997) 730-737